Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002101121 | SCV002395277 | likely benign | not provided | 2022-02-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003015291 | SCV003750473 | uncertain significance | Inborn genetic diseases | 2021-06-18 | criteria provided, single submitter | clinical testing | The c.5696G>A (p.R1899H) alteration is located in exon 27 (coding exon 26) of the SPTBN2 gene. This alteration results from a G to A substitution at nucleotide position 5696, causing the arginine (R) at amino acid position 1899 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004770404 | SCV005380345 | uncertain significance | not specified | 2024-08-22 | criteria provided, single submitter | clinical testing | Variant summary: SPTBN2 c.5696G>A (p.Arg1899His) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 5.6e-05 in 250344 control chromosomes, predominantly at a frequency of 9.8e-05 within the Non-Finnish European subpopulation in the gnomAD database. This frequency is not significantly higher than estimated for a pathogenic variant in SPTBN2 causing Spinocerebellar Ataxia 5, allowing no conclusion about variant significance. To our knowledge, no occurrence of c.5696G>A in individuals affected with Spinocerebellar Ataxia 5 and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 1589623). Based on the evidence outlined above, the variant was classified as uncertain significance. |